EU Agency Backs Nycomed’s Daxas After U.S. Rebuff

Reuters -- Privately owned Swiss drugmaker Nycomed, which is aiming for an initial public offering (IPO) at some stage, won a consolation prize on Friday as European regulators backed a key lung drug after a recent rebuff in the United States.